Piramal Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹1.58−₹2.46₹0.69₹0.14−₹1.57
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹1.58−₹2.46₹0.68₹0.14−₹1.57
₹61.50₹61.50₹61.35₹59.80₹56.76
₹73.68₹66.83₹69.10₹61.76₹59.34
—₹12.45₹6.74₹7.59₹4.05
₹5.75₹5.75₹1.72₹2.21−₹4.03
—₹0.14₹0.11₹0.00₹0.56
132.7132.7132.4132.3119.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹30,628 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-1.570.140.69-2.46-1.58
Diluted EPS-1.570.140.68-2.46-1.58
Book Value per Share56.7659.8061.3561.5061.50
Revenue per Share59.3461.7669.1066.8373.68
Cash Flow per Share4.057.596.7412.45—
Free Cash Flow per Share-4.032.211.725.755.75
Dividends per Share0.560.000.110.14—
Shares Outstanding (cr)119.3132.3132.4132.7132.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.